Quantcast
Last updated on April 17, 2014 at 10:06 EDT

Latest DelMar Pharmaceuticals Inc. Stories

2013-06-10 08:29:29

Company invites individual and institutional investors to log-on to view presentation NEW YORK, June 10, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) today announced that their June 6(th) RetailInvestorConferences.com presentation is now available for on-demand viewing. LINK: www.retailinvestorconferences.com > click on the red "register/ watch event now" button DelMar Pharmaceuticals, Inc.'s presentation will be available 24/7 for 90 days. Investors may...

2013-06-03 08:28:12

Activity with VAL-083 Observed in Recurrent Malignant Glioma and Progressive Secondary Brain Tumors VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company presented a poster entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual...

2013-05-31 08:24:05

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK, May 31, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) today announced that Jeffrey Bacha, B.Sc., MBA, President & CEO, will present at RetailInvestorConferences.com. DATE: June 6, 2013 TIME: 10:45 AM EDT LINK: www.retailinvestorconferences.com > click on the red "register /watch event now" button This will be a live,...

2013-05-28 08:28:39

VANCOUVER, British Columbia and MENLO PARK, Calif., May 28, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the company would present an abstract entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31 - June 4, 2013 in Chicago, Illinois, USA. DelMar will present new...

2013-05-20 08:27:01

VANCOUVER, Canada and MENLO PARK, Calif., May 20, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) announced today that Jeffrey Bacha, president and CEO, will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel. The Company's presentation is scheduled to begin at 11:30 a.m. EDT and will be available via a live webcast. To access the webcast, go to:...

2013-05-16 08:28:37

VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma") is pleased to provide the following update from President & CEO, Mr. Jeffrey Bacha: During the past quarter, we continued to advance our lead product candidate VAL-083 in an ongoing brain cancer clinical trial. Our current trial is a dose-escalating study designed to evaluate the safety and efficacy of VAL-083 as a potential treatment for...

2013-04-10 08:31:36

VANCOUVER, British Columbia and MENLO PARK, Calif., April 10, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C. during a clinical poster session entitled, "A Phase...

2013-04-01 12:25:48

VANCOUVER, British Columbia and MENLO PARK, Calif., April 1, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the company would present an abstract entitled "A Phase I/II study of VAL-083 in patients with recurrent malignant glioma or secondary brain tumor" at the American Association of Cancer Research (AACR) Annual Meeting, which is being held April 6 - 10, 2013 in Washington D.C., USA. DelMar will present new clinical data from its ongoing...

2013-03-13 08:33:38

VANCOUVER, British Columbia and MENLO PARK, Calif., March 13, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the Company has been named to Rocket Builder's 11(th) annual "Ready to Rocket" list. Rocket Builders "Ready to Rocket" list recognizes British Columbia technology companies that are best positioned to capitalize on the 2012 technology sector trends that will lead them to faster growth than their peers. According to Rocket Builders, the...

2013-03-11 08:27:14

VANCOUVER, British Columbia and MENLO PARK, Calif., March 11, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"), a clinical and commercial stage drug development company with a focus on the treatment of cancer, today announced that Jeffrey Bacha, President & CEO of DelMar, will present at the ROTH 25(th) Annual Growth Stock Conference in Laguna Niguel, CA at 5:00pm PDT on Monday, March 18(th), 2013. "We are pleased to present the DelMar story at the ROTH...